UnitedHealthcare denied your IVIG and immunoglobulin? Here is what to do next

Why UnitedHealthcare denies IVIG and immunoglobulin

UnitedHealthcare is the largest U.S. health insurer by membership and runs commercial, Medicare Advantage, and Medicaid plans. Denial volume is correspondingly high, but so is the reversal rate when appeals are filed correctly.

For IVIG and immunoglobulin specifically: Intravenous and subcutaneous immunoglobulin (IVIG, SCIG) is expensive, infused repeatedly, and reviewed against a short list of accepted diagnoses. Denials say 'not medically necessary' or 'experimental' for the specific condition, or move the drug to a different benefit or site of care.

What UnitedHealthcare denies for IVIG and immunoglobulin

The IVIG and immunoglobulin services most often denied:

• IVIG for CIDP, myasthenia gravis, dermatomyositis, or autoimmune encephalitis
• Continuation after the initial authorization period when response is not documented
• Dose or frequency above the policy's stated range
• Site-of-care changes: hospital outpatient infusion moved to home or a standalone center
• Subcutaneous immunoglobulin when the plan prefers intravenous

Why IVIG and immunoglobulin claims get denied

A typical UnitedHealthcare IVIG and immunoglobulin denial almost always cites one of these reasons. Each one maps to a specific rebuttal in the appeal:

• Diagnosis not on the plan's list of covered indications
• Required baseline labs (immunoglobulin levels, vaccine response, nerve conduction studies) not in the record
• No documented failure of first-line therapy where the policy requires it
• Response to prior IVIG cycles not documented in measurable terms
• Plan classifies the use as experimental or investigational

The UnitedHealthcare appeal process

Appeal levels: Internal level 1 (30 days for standard, 72h expedited), internal level 2 (in some states), then external/independent review. Medicare Advantage adds federal levels 2-5 (IRE → ALJ → Council → District Court).

Carrier timing: Standard appeals must be filed within 180 days of the denial date. Urgent designations compress carrier response time to 72 hours. Medicare Advantage level-2 deadline is 60 days from level-1 denial.

IVIG timing: Ongoing infusions make most IVIG appeals urgent: request expedited review and expect a decision within 72 hours (29 CFR 2560.503-1(f)(2)(i); 42 CFR 422.584 for Medicare Advantage). Internal appeal filing window: at least 180 days for commercial and employer plans; 65 days for Medicare Advantage; 60 days for Part D redetermination (42 CFR 423.582). External review must be requested within 4 months of the final internal denial for ACA-covered plans.

What we know about UnitedHealthcare: We file all UHC appeals with the criteria-disclosure request embedded in the cover letter. This anchors the procedural record from day one.

Common UnitedHealthcare denial patterns for IVIG and immunoglobulin

• Clinical criteria withheld in initial denial. UHC denials frequently cite 'not medically necessary' without disclosing the specific clinical criteria applied. Federal and state law require disclosure on request, and once disclosed, the criteria become the rebuttal map.
• Specialty-drug formulary denials. Specialty injectables are often denied at the pharmacy benefit (Optum Rx) before they reach the medical benefit. Filing a formulary exception with manufacturer clinical data is the standard reversal path.
• Medicare Advantage prior auth. UHC's Medicare Advantage plans have been the subject of multiple federal investigations into prior-auth denial rates. A substantial share of these denials reverse at level 1 once the appeal supplies the withheld clinical criteria; level 2 (IRE/Maximus) is where escalation cases tend to land.

How to win your UnitedHealthcare IVIG and immunoglobulin appeal

Strategy for IVIG and immunoglobulin: Request the plan's immunoglobulin policy and the reviewer's specialty. Have the treating specialist write to each criterion: diagnosis with supporting labs or electrodiagnostic studies, prior therapies and results, measurable response to IVIG, and dosing rationale. For off-label uses, attach the guideline or peer-reviewed evidence the specialist relies on and identify it accurately. If the denial is 'experimental', the external review process specifically covers that determination (45 CFR 147.136(d)).

Filed against UnitedHealthcare, that strategy rides on this procedural spine:

1. Procedural-rights anchor. Every UnitedHealthcare denial triggers ERISA § 503 or 45 C.F.R. § 147.136 procedural rights. The cover letter invokes these in the opening paragraph to lock the timeline and force criteria disclosure.
2. Criteria-disclosure demand. UnitedHealthcare frequently denies on "not medically necessary" without disclosing the clinical criteria applied. Once disclosed, those criteria become the rebuttal map.
3. Controlling-standard citation. Plans compare the diagnosis to their immunoglobulin policy, which typically lists FDA-labeled indications (primary immunodeficiency, immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, Kawasaki disease, and others) and selected off-label uses supported by published evidence. Medicare Part B covers immunoglobulin for primary immunodeficiency at home under 42 CFR 410.10 and the home IVIG benefit; other indications follow local coverage determinations in the Medicare Coverage Database. Plan criteria must be disclosed on request (29 CFR 2560.503-1(m)(8); 45 CFR 147.136).
4. Treating-provider attestation. A letter from the treating physician addressing each criterion in UnitedHealthcare's own policy language. This is the single strongest evidentiary element.
5. Requested action. A specific demand to reverse the IVIG and immunoglobulin denial and approve the service, not a general "please reconsider."

Documents you'll need for your UnitedHealthcare IVIG and immunoglobulin appeal

• The denial letter naming the criterion or policy applied
• Specialist's notes with diagnosis, labs, and electrodiagnostic or imaging results
• Record of prior therapies and outcomes
• Infusion records showing dose, frequency, and documented response
• The plan's immunoglobulin policy (request it in writing)

What a IVIG and immunoglobulin appeal can recover

Typical recovery for IVIG and immunoglobulin cases runs Immunoglobulin is among the most expensive recurring therapies; a denied course commonly represents thousands of dollars per infusion in billed charges.. The exact figure depends on the specific service and your plan's contracted rates.

UnitedHealthcare IVIG and immunoglobulin appeals: frequently asked questions

What Apellica does for UnitedHealthcare IVIG and immunoglobulin appeals

We file appeals against UnitedHealthcare specifically configured to its internal review process. Every IVIG and immunoglobulin appeal embeds the criteria-disclosure demand, the procedural-rights anchor, the controlling-standard citation above, treating-provider attestation language, and the peer-reviewed evidence relevant to the denied service.

Cost: $0 upfront. We work on contingency for UnitedHealthcare appeals, if the appeal succeeds, we collect a percentage of the recovered claim value. If it fails, you owe nothing.

Related UnitedHealthcare guides

• UnitedHealthcare surgery denials appeal guide
• UnitedHealthcare mri and imaging denials appeal guide
• UnitedHealthcare medication and prescription denials appeal guide
• UnitedHealthcare medicare denials appeal guide

IVIG and immunoglobulin guides for other carriers

• Aetna (CVS Health) IVIG and immunoglobulin appeal guide
• Cigna (Evernorth) IVIG and immunoglobulin appeal guide
• Anthem / BlueCross BlueShield IVIG and immunoglobulin appeal guide
• Humana IVIG and immunoglobulin appeal guide